Zhang M, Bai L, Chen J, Meng Q, et al. Clinical benefit of continuation of PD-1 inhibitors after progression on first-line chemoimmunotherapy in metastatic gastric cancer and biomarker exploration. BMC Cancer 2025;25:935.
PMID: 40413463